Results 151 to 160 of about 39,720 (193)

Confronting Multidrug-Resistant Tuberculosis

New England Journal of Medicine, 2012
Microbial resistance to antituberculosis drugs has existed since the dawn of the antibiotic era.1 Multidrug-resistant (MDR) tuberculosis, defined by resistance to isoniazid and rifampin, requires treatment for up to 2 years with expensive second-line drugs that have poor side-effect profiles; success rates rarely exceed 65 to 75%.
Richard E, Chaisson, Eric L, Nuermberger
openaire   +2 more sources

Multidrug-resistant tuberculosis

Infectious Disease Clinics of North America, 2002
Multidrug-resistant TB is a growing public health problem. Although control of the multidrug-resistant TB epidemic has been achieved in New York City, strains of multidrug-resistant TB are found in nearly every state. Much of the world faces a growing problem with no immediate solution.
openaire   +2 more sources

Treatment and Prevention of Multidrug-Resistant Tuberculosis [PDF]

Drugs, 1999
Multidrug-resistant tuberculosis (MDRTB), which is defined as combined resistance to isoniazid and rifampicin, is a 'man-made' disease that is caused by improper treatment, inadequate drug supplies or poor patient supervision. Patients with MDRTB face chronic disability and death, and represent an infectious hazard for the community.
Bastian, I., Colebunders, R.
openaire   +3 more sources

Multidrug‐Resistant Tuberculosis

Annals of the New York Academy of Sciences, 2001
Abstract: The costs of multidrug‐resistant tuberculosis (MDR TB) reach far beyond the cost of the clinical treatment of the patient. The first impact of the discovery of MDR TB in a population is the need to recognize that all TB patients have the potential of being MDR.
openaire   +2 more sources

Multidrug-Resistant Tuberculosis Spondylitis

Acta Clinica Belgica, 2000
We report a case of multidrug-resistant spinal tuberculosis complicated by epiduritis and paraspinal abscess in a 68-year-old black woman. Multidrug-resistant tuberculous spondylitis is still rare in Belgium. Two others cases were reported from 1992 to 1997.
Cherifi, Soraya, Guillaume, Marie-Paule, Peretz, Anne   +2 more
openaire   +3 more sources

Linezolid for multidrug-resistant tuberculosis

The Lancet Infectious Diseases, 2013
In their Comment in The Lancet Infectious Diseases, Kwok-Chiu Chang and colleagues concluded that expansion of access to linezolid for complicated cases of drug-resistant tuberculosis risks the loss of a potentially useful drug and could promote the emergence and spread of drug-resistant tuberculosis in the community.
Helen, Cox, Nathan, Ford, Jennifer, Hughes, Eric, Goemaere   +3 more
openaire   +2 more sources

Management of Multidrug-Resistant Tuberculosis

Chemotherapy, 1999
Drug-resistant tuberculosis (TB) originally is the product of inadequate therapy; this may entail noncompliance with treatment, interrupted drug supplies, or inappropriate prescription. Patients may sequentially acquire resistance to several drugs through repetition of this process.
openaire   +2 more sources

The challenge of multidrug resistant tuberculosis

Hospital Medicine, 2001
Multidrug resistant tuberculosis (MDRTB) is defined as resistance to the two principal drugs used to treat TB, isoniazid and rifampicin, whether there is resistance to other drugs or not. It is a relatively new phenomenon and poses one of the most difficult therapeutic problems in medicine because failure may not only mean death of the patient but ...
openaire   +2 more sources

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

New England Journal of Medicine, 2009
The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase. TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis.In the first stage of a two-stage, phase 2 ...
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., Venter, A., Allen, J., Palomino, J. C., De Marez, T., van Heeswijk, R. P. G., Lounis, N., Meyvisch, P., Verbeeck, J., Parys, W., de Beule, K., Andries, K., McNeeley, D. F.   +21 more
openaire   +4 more sources

Quinolones and Multidrug-Resistant Tuberculosis

Chemotherapy, 1999
The prevalence of initial resistance of multidrug-resistant tuberculosis (MDR-TB) to at least isoniazid (INH) and rifampicin (RFP) in Thailand during the period 1993–1997 is reported; in this era, trends for INH + RFP + streptomycin (SM) and ethambutol (EMB), INH + RFP + SM or EMB and MDR-TB were stable. The prevalence of acquired MDR-TB is on a slight
openaire   +2 more sources